News for Immunic Inc Stock (IMUX)

Immunic, Inc. Announces Pricing of $90.0 Million Public Offering of Common Stock

PRNewsWire • 08/05/20

Immunic, Inc. Announces Proposed Public Offering of 5 Million Shares of Common Stock

PRNewsWire • 08/03/20

Immunic, Inc. (IMUX) CEO Daniel Vitt on Q2 2020 Results - Earnings Call Transcript

Seeking Alpha • 08/03/20

Immunic Soars On Positive Mid-Stage Readout For Multiple Sclerosis Study, Q2 Beat

Benzinga • 08/03/20

Immunic, Inc. to Report Second Quarter 2020 Financial Results and Provide Corporate Update

PRNewsWire • 07/30/20

Immunic, Inc. Announces First Patients Enrolled in Investigator-Sponsored Phase 2 Clinical Trial of IMU-838 in Combination with Oseltamivir for the Treatment of Patients with Moderate-to-Severe COVID-19

PRNewsWire • 07/27/20

Antivirals In The COVID-19 Space

Seeking Alpha • 07/13/20

Immunic, Inc. to Join Russell 3000® Index

PRNewsWire • 06/22/20

Immunic, Inc. Announces First Patients Dosed in its Phase 2, CALVID-1 Clinical Trial of IMU-838 in COVID-19

PRNewsWire • 06/15/20

Why Immunic (IMUX) Stock Might be a Great Pick

Zacks Investment Research • 06/11/20

Immunic Gets FDA Allowance for Phase II Coronavirus Study

Zacks Investment Research • 06/10/20

Immunic, Inc. Announces Pricing of $25 Million Public Offering of Common Stock

PRNewsWire • 06/10/20

Immunic, Inc. Announces U.S.

PRNewsWire • 06/09/20

Immunic, Inc. to Participate in Investor and Industry Conferences in June

PRNewsWire • 05/29/20

Immunic, Inc. to Host Virtual R&D Day Today, May 19, 2020

PRNewsWire • 05/19/20